Mio Matsubara
Overview
Explore the profile of Mio Matsubara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shijo T, Fukui A, Sakurada Y, Terao N, Yoneyama S, Kusada N, et al.
Ophthalmic Genet
. 2024 Nov;
46(1):25-30.
PMID: 39523750
Purpose: To investigate whether genetic and clinical characteristics differ depending on generations using 326 patients (male/female, 259/67; mean age, 55.4 ± 12.5 years) with simple CSC. Methods: All patients were...
2.
Kimura M, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Kasai Y, et al.
Pharmaceuticals (Basel)
. 2024 Jun;
17(6).
PMID: 38931354
Purpose: We compared 12-month outcomes of eyes with polypoidal choroidal vasculopathy (PCV) with or without complete regression of polyps observed one month after three monthly intravitreal administrations (loading phase) of...
3.
Kikushima W, Sakurada Y, Fukuda Y, Matsubara M, Yoneyama S, Shijo T, et al.
Retina
. 2024 Feb;
44(3):498-505.
PMID: 38376852
Purpose: To investigate the characteristics of patients with over a 12-month remission after 3 monthly intravitreal aflibercept injections followed by a pro re nata regimen for exudative age-related macular degeneration...
4.
Fukuda Y, Sakurada Y, Matsubara M, Kotoda Y, Kasai Y, Sugiyama A, et al.
Jpn J Ophthalmol
. 2023 Jun;
67(4):402-409.
PMID: 37289296
Purpose: To compare the one-year visual and anatomic outcomes of an as-needed regimen of brolucizumab and aflibercept for polypoidal choroidal vasculopathy (PCV). Study Design: A retrospective comparative study. Methods: A...
5.
Kikushima W, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Sugiyama A, et al.
Pharmaceuticals (Basel)
. 2023 Apr;
16(4).
PMID: 37111318
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months....
6.
Shigemoto Y, Hasebe Y, Kitamura K, Fukuda Y, Sakamoto M, Matsubara M, et al.
J Clin Med
. 2023 Apr;
12(7).
PMID: 37048542
Purpose: To investigate how many tests need to be performed to adequately assess intraocular pressure (IOP) diurnal change using a self-measuring rebound tonometer among glaucoma patients. Subjects And Methods: Adult...
7.
Kitamura K, Fukuda Y, Hasebe Y, Matsubara M, Kashiwagi K
J Clin Med
. 2023 Mar;
12(6).
PMID: 36983331
Background: The evaluation of ab interno trabeculectomy, referred to as trabectome, among Japanese patients is insufficient. Subjects And Methods: Japanese patients who underwent trabectome at the University of Yamanashi Hospital...
8.
Yoneyama S, Fukui A, Sakurada Y, Terao N, Shijo T, Kusada N, et al.
Retina
. 2023 Feb;
43(3):389-395.
PMID: 36729824
Purpose: To compare the clinical and genetic characteristics of simple and complex central serous chorioretinopathy using central serous chorioretinopathy international group criteria. Methods: Patients with idiopathic central serous chorioretinopathy were...
9.
Kikushima W, Sakurada Y, Sugiyama A, Yoneyama S, Matsubara M, Fukuda Y, et al.
Sci Rep
. 2022 Nov;
12(1):18420.
PMID: 36319691
Hyperreflective foci (HRF) are the findings observed in optical coherence tomography (OCT) in several retinal diseases and are believed to be associated with the increased risk of atrophy in eyes...
10.
Yoneyama S, Fukui A, Sakurada Y, Terao N, Shijo T, Kusada N, et al.
Sci Rep
. 2022 Jun;
12(1):10565.
PMID: 35732691
To investigate the differences in clinical and genetic characteristics between males and females with central serous chorioretinopathy (CSC). Consecutive 302 patients (mean age; 56.3 ± 11.7, male/female: 249/53) with CSC...